Register to get unlimited access to Citywire’s fund manager database. Registration is free and only takes a minute.
Please see terms and conditions for restrictions on use of Citywire's Fund Manager database.

This Fund Manager Rating is based on the Citywire Long Only ratings methodology

Citywire Ratings are rewarded for risk adjusted outperformance of benchmarks we select independently More information on how Ratings are calculated

Evan McCulloch

Evan McCulloch

Showing manager performance in Gibraltar View performance globally

About Evan McCulloch

Evan McCulloch joined Franklin Templeton Investments as a management trainee in 1992. Now a vice president and portfolio manager for the group, McCulloch’s responsibilities include managing the Franklin Biotechnology Fund. A self described research driven investor, McCulloch specialises in research analysis of the health care industry; including pharmaceuticals, health care information systems/internet and health care providers. He is a bottom-up investor who pursues a growth strategy and focuses primarily on individual securities, choosing companies he believes are positioned for rapid growth in revenues, earnings or assets. Born in Mesa, Arizona in 1969, McCulloch graduated from the University of California at Berkeley with a bachelor’s degree in economics and business administration.

Are you Evan McCulloch?

Citywire Rating: Not Rated

2013

  • FNot rated in Feb 2013
  • MNot rated in Mar 2013
  • ANot rated in Apr 2013
  • MNot rated in May 2013
  • JNot rated in Jun 2013
  • JNot rated in Jul 2013
  • ANot rated in Aug 2013
  • SNot rated in Sep 2013
  • ONot rated in Oct 2013
  • NNot rated in Nov 2013
  • DNot rated in Dec 2013

2014

  • JNot rated in Jan 2014
  • FNot rated in Feb 2014
  • MNot rated in Mar 2014
  • ANot rated in Apr 2014
  • MNot rated in May 2014
  • JNot rated in Jun 2014
  • JNot rated in Jul 2014
  • ANot rated in Aug 2014
  • SNot rated in Sep 2014
  • ONot rated in Oct 2014
  • NNot rated in Nov 2014
  • DNot rated in Dec 2014

2015

  • JNot rated in Jan 2015
  • FNot rated in Feb 2015
  • MNot rated in Mar 2015
  • ANot rated in Apr 2015
  • MNot rated in May 2015
  • JNot rated in Jun 2015
  • JNot rated in Jul 2015
  • ANot rated in Aug 2015
  • SNot rated in Sep 2015
  • ONot rated in Oct 2015
  • NNot rated in Nov 2015
  • DNot rated in Dec 2015

2016

  • JNot rated in Jan 2016
  • FNot rated in Feb 2016
  • MNot rated in Mar 2016
  • ANot rated in Apr 2016
  • MNot rated in May 2016
  • JNot rated in Jun 2016
  • JNot rated in Jul 2016
  • ANot rated in Aug 2016
  • SNot rated in Sep 2016
  • ONot rated in Oct 2016
  • NNot rated in Nov 2016
  • DRated Plus in Dec 2016

2017

  • JRated Plus in Jan 2017
  • FNot rated in Feb 2017
  • MNot rated in Mar 2017
  • ANot rated in Apr 2017
  • MRated Plus in May 2017
  • JRated Plus in Jun 2017
  • JRated Plus in Jul 2017
  • ANot rated in Aug 2017
  • SNot rated in Sep 2017
  • ONot rated in Oct 2017

Performance

Equity - Biotechnology
over : 30/09/2016 - 30/09/2017

Total Return

Month by Month Performance

Quarterly Performance

to 30/09/2017 Annual Q1 Q2 Q3 Q4
2017 10.9% -2.0% 5.2%
2016 -2.0% -22.4% 9.2% 17.4% -1.6%
2015 11.0% 19.9% -1.6% -16.5% 12.8%
2014 43.1% 6.7% 0.5% 15.3% 15.7%
2013 61.2% 27.0% 8.2% 15.7% 1.4%
2012 -5.6%

Related News

Franklin Templeton boosts blockbuster biotech team

US giant assigns third person to oversee dedicated equity investment vehicle, Citywire Selector learns.

Politics will not 'kill the golden goose', says biotech specialist

Franklin Templeton's Evan McCulloch is braced for potential disruption from Presidential race but believes idiosyncratic stories can stand up to the task.

Franklin Templeton reopens blockbuster biotech fund

US giant ends soft-close measures after 18-months following fall in assets under management and market correction.

Biotech manager departs Franklin Templeton

Sector specialist ends three-year stint on soft-closed strategy with pharma expert named as replacement, Citywire Global has learned.

Biotech equity’s most consistent managers of the past five years

Citywire Global uncovers the pair of sector specialists continually staying ahead of the average peer over the past half-decade.

Bright lights in biotech: two most consistent managers revealed

The specialist health care sector has received increased interest over the past five years but only two managers have regularly beaten the average manager.

Franklin Templeton soft-closes star European manager's €3bn fund

The fund co-managed by a Citywire AA-rated manager has seen its assets rise €600 million over the last six months, Citywire Global can reveal.

Golden gains: five top US managers trade views on equities

VIDEO: Matt Goodburn reports from California where leading managers from Neptune, PIMCO, Matthews Asia and Franklin Templeton reveal their equity expectations for 2014.

This isn’t a bubble, it’s an R&D boom, says top biotech manager

Despite rapid multiple expansion, the fundamentals are solid, says Franklin Templeton’s Evan McCulloch.

Citywire Discovery Source: Citywire Discovery Performance is for the period shown (month end to month end, bid/bid, gross income reinvested, calculated in the currency and currencies indicated)..Portions of the information contained on this page was derived by Citywire Financial Publishers Ltd using content supplied by Lipper, A Reuters Company.